Gilead and LEO Pharma Collaborate on STAT6 Inflammatory Disease Programmes

Partnership Details:
Gilead Sciences and LEO Pharma have entered into a strategic partnership worth up to $1.7 billion to advance LEO’s small molecule oral STAT6 programme for inflammatory diseases13.

Deal Structure:
The deal includes an upfront payment of $250 million to LEO Pharma, with potential additional payments of approximately $1.5 billion in development, regulatory, and commercial milestones13.

Rights and Responsibilities:
Gilead will have global rights to develop, manufacture, and commercialize the oral STAT6 programme, while LEO Pharma retains exclusive global rights to topical STAT6 formulations in dermatology and has the option to co-commercialize oral programmes for dermatology indications outside the US13.

Royalties:
LEO Pharma may receive tiered royalties on sales of oral STAT6 products, and Gilead could earn royalties on sales of topical STAT6 products13.

STAT6 Significance:
STAT6 is a transcription factor crucial for IL-4 and IL-13 cytokine signaling, which are validated targets for Th2-mediated inflammatory conditions such as atopic dermatitis, asthma, and chronic obstructive pulmonary disease13.

Development Goals:
The partnership aims to explore the potential of the STAT6 pathway to bring forward an oral option for patients suffering from chronic inflammatory conditions, offering an alternative to injectable biologics13.

Sources:

1. https://pmlive.com/pharma_news/gilead-and-leo-enter-inflammatory-disease-partnership-worth-up-to-1-7bn/

3. https://www.pharmaceutical-technology.com/news/gilead-leo-stat6-inflammatory/